TRUDI: TDXD+Durva in HER2+/Low IBC
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
- Status
- RECRUITING
- Phase
- PHASE3
PIK3CA in HER2+ BC and pCR Trial
- Status
- UNKNOWN
- Phase
- NA
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Thero2-01S22 in HER2-positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
- Status
- COMPLETED
- Phase
- N/A
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
- Status
- RECRUITING
- Phase
- PHASE1
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3